Olaparib: all 338 studies that test it

Page 1 of 4. Open to participants first (61), then studies with results posted, then the rest; newest registration first within each.

• Phase 1/2 Study Of PARP Inhibition With Olaparib To Enhance The Efficacy Of High-Dose Chemotherapy In Refractory And Relapsed Germ Cell TumorsNot yet recruitingNCT07850973Phase 1/2
• Fluzoparib + Bevacizumab vs Olaparib + Bevacizumab for Maintenance Therapy in HRD-Positive Advanced Ovarian CancerNot yet recruitingNCT07647653Phase 2
• The PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian CancerRecruitingNCT07460180Phase 1/2
• Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian CancerNot yet recruitingNCT07407452Phase 2
• Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP LossRecruitingNCT07382544Phase 1
• QL1706 With Olaparib for Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency (HRD)Not yet recruitingNCT07113964Phase 2
• Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate CancerNot yet recruitingNCT07090369Phase 1
• A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian CancerRecruitingNCT07069335Phase 1
• Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast CancerNot yet recruitingNCT07005583Phase 2
• Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian CancerRecruitingNCT06856499Phase 1
• Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment ExhaustionRecruitingNCT06739395Phase 2
• Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for p53abn Endometrial CancerRecruitingNCT06712472Phase 3
• Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian CancerRecruitingNCT06686030Phase 2
• NEoadjuvant Olaparib Combination OvArian Cancer Targeted StudyNot yet recruitingNCT06650709Phase 2
• Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).RecruitingNCT06607692Phase 1/2
• Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian CancerRecruitingNCT06580314Phase 3
• Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast CancerRecruitingNCT06488378Phase 1
• Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)RecruitingNCT06441747Phase 2
• Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)Enrolling by invitationNCT06419179Phase 2
• Status of HRD That Lead to a Benefit From Olaparib in Combination With Bevacizumab (STROBE Trial)RecruitingNCT06377267Phase 2
• Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLCRecruitingNCT06217757Phase 1/2
• Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast CancerRecruitingNCT06201234Phase 2
• Olaparib in PALB2 Advanced Pancreatic CancerRecruitingNCT06078787Phase 2
• OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older AdultsNot yet recruitingNCT05949424Phase 4
• Estradiol Plus Olaparib for Breast Cancer (PHOEBE)RecruitingNCT05900895Phase 1
• An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and OlaparibRecruitingNCT05887609Phase 2
• Improving Peptide Receptor Radionuclide Therapy With PARP InhibitorsRecruitingNCT05870423Phase 1
• Olaparib Maintenance Therapy in Metastatic Breast CancerRecruitingNCT05629429Phase 2
• Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)RecruitingNCT05623319Phase 2
• Pembro With Radiation With or Without OlaparibRecruitingNCT05568550Phase 2
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialRecruitingNCT05564377Phase 2
• Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast CancerNot yet recruitingNCT05522491Phase 2
• Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast CancerRecruitingNCT05485766Phase 2
• Pilot Trial for Treatment of Recurrent GlioblastomaRecruitingNCT05432518Early Phase 1
• Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)RecruitingNCT05332561Phase 2
• MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients.RecruitingNCT05255471Phase 3
• MITO 35a: Olaparib Maintenance Therapy in Newly Diagnosed BRCA Wild-type Advanced Ovarian, Fallopian Tube and Primitive Peritoneal CancerRecruitingNCT05233982Phase 2
• Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)Not yet recruitingNCT05128734Phase 2
• Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic CancerRecruitingNCT05093231Phase 2
• APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 MutationRecruitingNCT04858334Phase 2
• A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast CancerRecruitingNCT04683679Phase 2
• Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian CancerRecruitingNCT04633239Phase 1
• Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) CancerRecruitingNCT04592211Phase 1/2
• Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian CancerRecruitingNCT04585958Phase 1
• A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLCRecruitingNCT04550104Phase 1
• Olaparib in Patients With HRD Malignant MesotheliomaRecruitingNCT04515836Phase 2
• Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)RecruitingNCT04086485Phase 1/2
• Carboplatin or Olaparib for BRcA Deficient Prostate CancerRecruitingNCT04038502Phase 2
• Targeted Pathway Inhibition in Patients With Pancreatic CancerRecruitingNCT04005690Early Phase 1
• Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene MutationsRecruitingNCT03786796Phase 2
• Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor MalignanciesRecruitingNCT03772561Phase 1
• WIRE - Novel Treatments in Renal Cell CancerRecruitingNCT03741426Phase 2
• PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast CancerRecruitingNCT03740893Phase 2
• Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)RecruitingNCT03486873Phase 3
• Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)RecruitingNCT03297606Phase 2
• Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast CancerRecruitingNCT03150576Phase 2/3
• The Drug Rediscovery Protocol (DRUP Trial)RecruitingNCT02925234Phase 2
• European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory TumorsRecruitingNCT02813135Phase 1/2
• TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerRecruitingNCT02693535Phase 2
• Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatmentRecruitingNCT02029001Phase 2
• I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingNCT01042379Phase 2
• Phase 1 Trial of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid TumorsTerminatedNCT06560632Phase 1Results posted
• Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate CancerTerminatedNCT05501548Phase 2Results posted
• Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 MutationsActive, not recruitingNCT05457257Phase 4Results posted
• Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped WorkingActive, not recruitingNCT05432791Phase 2/3Results posted
• RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic LeukemiaTerminatedNCT05405309Phase 1/2Results posted
• Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric CancersCompletedNCT05379972Phase 2Results posted
• Olaparib in Subjects With Advanced Pancreatic Acinar Cell CarcinomaTerminatedNCT05286827Phase 2Results posted
• A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With Breast Cancer Gene (BRCA) Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast CancerCompletedNCT05258747Phase 1Results posted
• A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast CancerActive, not recruitingNCT05203445Phase 2Results posted
• Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)Active, not recruitingNCT05171816Phase 3Results posted
• Olaparib for the Treatment of Castration Resistant Prostate AdenocarcinomaTerminatedNCT04951492Phase 2Results posted
• Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic AgentsActive, not recruitingNCT04739800Phase 2Results posted
• Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation DetectedTerminatedNCT04729387Phase 3Results posted
• PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)TerminatedNCT04556617Phase 1/2Results posted
• Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine TumorsTerminatedNCT04538378Phase 2Results posted
• Pembrolizumab and Olaparib in Cervical Cancer PatientsTerminatedNCT04483544Phase 2Results posted
• Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)CompletedNCT04456699Phase 3Results posted
• Olaparib With Ceralasertib in Recurrent OsteosarcomaActive, not recruitingNCT04417062Phase 2Results posted
• Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian CancerTerminatedNCT04377087Phase 2Results posted
• Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen LoadTerminatedNCT04336943Phase 2Results posted
• Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast CancerCompletedNCT04330040Phase 4Results posted
• Study of Pembrolizumab and Olaparib in Bile Duct CancerCompletedNCT04306367Phase 2Results posted
• Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial CancerActive, not recruitingNCT04269200Phase 3Results posted
• Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric AdenocarcinomaCompletedNCT04209686Phase 2Results posted
• Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR StudyActive, not recruitingNCT04197713Phase 1Results posted
• Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)TerminatedNCT04191135Phase 2Results posted
• TMZ + Olaparib for MGMT Hypermethylated Colorectal CancerCompletedNCT04166435Phase 2Results posted
• Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic SarcomaCompletedNCT04076579Phase 2Results posted
• Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene MutationsActive, not recruitingNCT04042831Phase 2Results posted
• A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)CompletedNCT03976362Phase 3Results posted
• Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)CompletedNCT03976323Phase 3Results posted
• Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) MutationActive, not recruitingNCT03953898Phase 2Results posted
• A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine LeiomyosarcomaActive, not recruitingNCT03880019Phase 2Results posted
• Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant TumorsActive, not recruitingNCT03878095Phase 2Results posted
• Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected MutationsActive, not recruitingNCT03842228Phase 1Results posted
• Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)CompletedNCT03834519Phase 3Results posted
• A Study of Olaparib and Durvalumab in Prostate CancerTerminatedNCT03810105Phase 2Results posted
• AMTEC IIT: Phase 2 Multiarm Study in TNBCTerminatedNCT03801369Phase 2Results posted
• Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)Active, not recruitingNCT03787680Phase 2Results posted

← Olaparib overview